Display options
Share it on

Arch Otorhinolaryngol. 1976 Jul 20;212(3):203-11. doi: 10.1007/BF00456699.

A clinical study on the ototoxic effects of tobramycin.

Archives of oto-rhino-laryngology

W Lehmann, R Häusler, F A Waldvogel

PMID: 1086087 DOI: 10.1007/BF00456699


In a clinical, prospective, non-randomized study, tobramycin has shown its high antibacterial activity in Gram-negative bacillary infections. The incidence of ototoxic side effects was very low: none of 18 patients studied before, at the end and 9 months after completion of tobramycin therapy showed any change in pure tone audiograms. Five of these 18 patients had renal impairment: 3 of them developed subjective and objective evidence of vestibular dysfunction, as demonstrated by caloric vestibulometry. However, these bilateral vestibular lesions all proved to be reversible a few weeks after cessation of therapy. Despite the low incidence and the reversibility of the ototoxic side effects, it seems advisable to monitor patients on long-duration tobramycin therapy for signs of vestibular dysfunction, particularly in cases of renal insufficiency.


  1. Antimicrob Agents Chemother. 1972 May;1(5):412-6 - PubMed
  2. Antimicrob Agents Chemother (Bethesda). 1967;7:341-8 - PubMed
  3. Acta Pathol Microbiol Scand B Microbiol Immunol. 1971;217:Suppl 217:1+ - PubMed
  4. Antimicrob Agents Chemother (Bethesda). 1967;7:324-31 - PubMed
  5. Antimicrob Agents Chemother. 1972 Sep;2(3):164-72 - PubMed
  6. N Engl J Med. 1972 Mar 16;286(11):583-6 - PubMed
  7. Appl Microbiol. 1971 Dec;22(6):1147-51 - PubMed
  8. Antimicrob Agents Chemother. 1972 Apr;1(4):340-2 - PubMed


MeSH terms

Publication Types